bumetanide has been researched along with Schizophrenia in 6 studies
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Atefimanash, P | 1 |
| Pourhamzeh, M | 1 |
| Susanabadi, A | 1 |
| Arabi, M | 1 |
| Jamali-Raeufy, N | 1 |
| Mehrabi, S | 3 |
| Kim, HR | 1 |
| Rajagopal, L | 1 |
| Meltzer, HY | 1 |
| Martina, M | 1 |
| Merner, ND | 1 |
| Mercado, A | 1 |
| Khanna, AR | 1 |
| Hodgkinson, A | 1 |
| Bruat, V | 1 |
| Awadalla, P | 1 |
| Gamba, G | 1 |
| Rouleau, GA | 1 |
| Kahle, KT | 1 |
| Rahmanzadeh, R | 2 |
| Shahbazi, A | 2 |
| Ardakani, MK | 1 |
| Rahmanzade, R | 2 |
| Joghataei, MT | 2 |
| Eftekhari, S | 1 |
| Khodaei Ardakani, MR | 1 |
| Barati, M | 1 |
| Bou Khalil, R | 1 |
2 trials available for bumetanide and Schizophrenia
| Article | Year |
|---|---|
Lack of the effect of bumetanide, a selective NKCC1 inhibitor, in patients with schizophrenia: A double-blind randomized trial.
Topics: Bumetanide; Double-Blind Method; Humans; Outcome Assessment, Health Care; Schizophrenia; Sodium Pota | 2017 |
Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial.
Topics: Adult; Bumetanide; Double-Blind Method; Female; Follow-Up Studies; Hallucinations; Humans; Male; Mid | 2017 |
4 other studies available for bumetanide and Schizophrenia
| Article | Year |
|---|---|
Hippocampal chloride transporter KCC2 contributes to excitatory GABA dysregulation in the developmental rat model of schizophrenia.
Topics: Animals; Bumetanide; Diuretics; gamma-Aminobutyric Acid; Hippocampus; K Cl- Cotransporters; Male; Pr | 2021 |
Depolarizing GABA
Topics: Animals; Bumetanide; Cognitive Dysfunction; Disease Models, Animal; gamma-Aminobutyric Acid; Mice; P | 2021 |
Gain-of-function missense variant in SLC12A2, encoding the bumetanide-sensitive NKCC1 cotransporter, identified in human schizophrenia.
Topics: Animals; Autism Spectrum Disorder; Bumetanide; Cohort Studies; Intellectual Disability; Membrane Pot | 2016 |
Is insulin growth factor-1 the future for treating autism spectrum disorder and/or schizophrenia?
Topics: Animals; Autism Spectrum Disorder; Brain; Bumetanide; Child; Child, Preschool; Chlorides; Endocannab | 2017 |